ICIs (** Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Tecentriq (atezolizumab) **)

Other Medications

EU med_ema_approved ES med_spain_hospital_use med_crc_approved 1 Clinical Trials

Description

ICIs are used for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after progression on fluoropyrimidine, oxaliplatin and irinotecan; they have shown efficacy in patients with MSI-H/dMMR tumors but not typically in those with microsatellite stable (MSS) CRC.

Mechanism of Action

ICIs, such as pembrolizumab and nivolumab, block the PD-1 receptor on T-cells, enhancing their ability to recognize and attack cancer cells; ipilimumab targets CTLA-4, another immune checkpoint, thereby activating a broader T-cell response.

Side Effects

Immune-mediated adverse reactions; fatigue; diarrhea; rash; pruritus

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04584008 Not Applicable
Active, not recruiting
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
China

Quick Info

Brand Name** Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Tecentriq (atezolizumab) **
CategoryOther Medications
EU Estado EMAmed_ema_approved
ES Acceso Españamed_spain_hospital_use med_crc_approved
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.